Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s president and CEO, Lisa Ricciardi will participate in two investor conferences in September.

September 2024 Investor Conferences

Event: Chardan Capital Markets Leadership Call   
Date/Time: September 5, 2024, at 11:00am ET
Livestream: Individuals interested in attending the live virtual event can email corpaccess@chardan.com

Event: H.C. Wainwright 26th Annual Global Investment Conference  
Date/Time: September 9-11, 2024
Webcast: Available On-Demand beginning September 9th at 7:00am ET

“We recently presented results from the Phase 2, proof-of-concept, SHINE study showing our orally delivered CT1812 slowed the progression of mild-to-moderate Alzheimer’s disease after just six months of treatment,” said CEO Lisa Ricciardi. “These upcoming events provide important opportunities to engage with investors as we advance our clinical programs for CT1812 in Alzheimer’s disease, with the SHIMMER Phase 2 study readout expected by year-end 2024.”

Archived webcasts of these presentations will be available on the “events and presentations” section of Cognition’s investor relations site.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is discovering and developing first-in-class small molecule therapeutics targeting degenerative disorders of the central nervous system and retina. Our lead candidate CT1812 is in multiple clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). We believe CT1812 can regulate pathways that are impaired in these diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, excluding statements of historical facts and statements related to current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. You should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities and costs related thereto; uncertainties related to the conduct and results of clinical trials; the timing, scope and likelihood of regulatory filings and regulatory approvals of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; the evolution of the markets in which we compete; our ability to implement our continue to innovate; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties that we may face. Consider such risk factors carefully when considering Cognition Therapeutics’ prospects. Any forward-looking statements represent Cognition Therapeutics’ beliefs and assumptions only as of the date of this press release and September conference presentations. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information: Cognition Therapeutics, Inc. info@cogrx.com

Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com